Pancreatic cancer is among the most aggressive cancer types, with survival rates being very low and current treatment being quite ineffective. To address this unmet medical need, HCW Biologics Inc. has developed and presented preclinical data for their T-cell engager approach – HCW11-018.

Antengene Corp. Ltd. has outlined progress in its early-stage pipeline. The company has leveraged its Antengager T-cell engager (TCE) platform for the discovery of multiple investigational programs.

Cue Biopharma Inc. and Immunoscape Pte. Ltd. have entered into a collaboration and license agreement for the treatment of solid tumors.

CDR-609 is a T-cell engager therapeutic from CDR-Life Inc. that targets Leucine-rich repeat-containing G protein-coupled receptor 5 (LGR5) with potential for treating colorectal cancer.

Takeda Pharmaceutical Co. Ltd. is exiting all work in cell therapies and will seek an external partner to advance the company’s research and clinic-ready cell therapy programs, the company said, noting that it is not currently running any clinical trials using cell therapy technology.

Cartography Biosciences Inc. has closed a $67 million series B financing to support its pipeline of T-cell engaging bispecific and multispecific antibody therapeutics that target novel and highly specific tumor antigens.

Takeda Pharmaceutical Co. Ltd. is exiting all work in cell therapies and will seek an external partner to advance the company’s research and clinic-ready cell therapy programs, the company said, noting that it is not currently running any clinical trials using cell therapy technology.

Boehringer Ingelheim Pharma GmbH & Co KG has advanced a novel T-cell engager resulting from a collaboration with Numab Therapeutics AG into preclinical development for the treatment of lung and gastrointestinal cancers.